Loading...
Loading...
PTCT| Name | Value |
|---|---|
| Revenues | 213.8M |
| Cost of Revenue | 12.7M |
| Gross Profit | 201.1M |
| Operating Expense | 321.7M |
| Operating I/L | -209.5M |
| Other Income/Expense | -27.9M |
| Interest Income | 29.4M |
| Pretax | -237.5M |
| Income Tax Expense | -38.6M |
| Net Income/Loss | -198.9M |
PTC Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of medicines for rare disorders. Their portfolio includes commercial products and candidates in various development stages, focusing on treatments for rare diseases. They offer Translarna and Emflaza for Duchenne muscular dystrophy, Tegsedi and Waylivra for rare diseases, and Evrysdi for spinal muscular atrophy. The company's splicing platform includes PTC518 for Huntington's disease. PTC Therapeutics has collaborations with F. Hoffman-La Roche Ltd, the Spinal Muscular Atrophy Foundation, and Akcea Therapeutics, Inc. to advance drug discovery and commercialize treatments for rare diseases.
